Research Analysts Issue Forecasts for Blueprint Medicines Co.’s FY2027 Earnings (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Research analysts at Leerink Partnrs issued their FY2027 earnings estimates for shares of Blueprint Medicines in a report released on Monday, May 6th. Leerink Partnrs analyst A. Berens anticipates that the biotechnology company will post earnings per share of $5.34 for the year. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($5.38) per share.

A number of other research analysts have also recently issued reports on BPMC. Barclays lifted their target price on Blueprint Medicines from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, May 3rd. HC Wainwright upped their price objective on shares of Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Citigroup raised their target price on shares of Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a research report on Friday, May 3rd. SVB Leerink upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating and upped their price target for the stock from $50.00 to $97.00 in a report on Monday. Finally, Stifel Nicolaus raised their price objective on Blueprint Medicines from $120.00 to $130.00 and gave the company a “buy” rating in a report on Friday, April 26th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines currently has an average rating of “Hold” and an average price target of $100.31.

Blueprint Medicines Price Performance

Blueprint Medicines stock opened at $108.55 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76. Blueprint Medicines has a 52 week low of $43.89 and a 52 week high of $110.93. The stock has a market capitalization of $6.64 billion, a P/E ratio of -22.57 and a beta of 0.65. The stock has a fifty day moving average of $92.17 and a 200-day moving average of $81.81.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. The business had revenue of $71.96 million for the quarter, compared to analysts’ expectations of $67.34 million. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm’s quarterly revenue was up 85.5% compared to the same quarter last year. During the same period last year, the firm posted ($2.65) earnings per share.

Insiders Place Their Bets

In other news, CFO Michael Landsittel sold 10,000 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the completion of the sale, the chief financial officer now directly owns 47,286 shares in the company, valued at $4,965,030. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Blueprint Medicines news, CFO Michael Landsittel sold 10,000 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total transaction of $1,050,000.00. Following the sale, the chief financial officer now owns 47,286 shares of the company’s stock, valued at $4,965,030. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher K. Murray sold 5,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total value of $500,000.00. Following the completion of the transaction, the insider now directly owns 24,495 shares of the company’s stock, valued at $2,449,500. The disclosure for this sale can be found here. In the last 90 days, insiders sold 104,123 shares of company stock worth $9,554,679. 3.88% of the stock is currently owned by insiders.

Institutional Trading of Blueprint Medicines

Large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in Blueprint Medicines by 1.6% in the third quarter. Bank of New York Mellon Corp now owns 266,744 shares of the biotechnology company’s stock worth $13,396,000 after purchasing an additional 4,127 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Blueprint Medicines by 9.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,055 shares of the biotechnology company’s stock valued at $605,000 after buying an additional 1,052 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Blueprint Medicines by 4.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 37,269 shares of the biotechnology company’s stock worth $1,872,000 after buying an additional 1,417 shares during the period. Emerald Advisers LLC boosted its holdings in Blueprint Medicines by 22.4% in the third quarter. Emerald Advisers LLC now owns 607,037 shares of the biotechnology company’s stock worth $30,485,000 after acquiring an additional 110,984 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust grew its stake in Blueprint Medicines by 12.3% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 464,321 shares of the biotechnology company’s stock valued at $23,318,000 after acquiring an additional 50,994 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.